ATRA vs. AURA, KALV, ORGO, VALN, ETON, PRME, ENGN, KRRO, RGNX, and GLUE
Should you be buying Atara Biotherapeutics stock or one of its competitors? The main competitors of Atara Biotherapeutics include Aura Biosciences (AURA), KalVista Pharmaceuticals (KALV), Organogenesis (ORGO), Valneva (VALN), Eton Pharmaceuticals (ETON), Prime Medicine (PRME), enGene (ENGN), Korro Bio (KRRO), REGENXBIO (RGNX), and Monte Rosa Therapeutics (GLUE). These companies are all part of the "pharmaceutical products" industry.
Atara Biotherapeutics vs.
Aura Biosciences (NASDAQ:AURA) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, community ranking, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.
In the previous week, Atara Biotherapeutics had 10 more articles in the media than Aura Biosciences. MarketBeat recorded 13 mentions for Atara Biotherapeutics and 3 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 0.71 beat Atara Biotherapeutics' score of -0.27 indicating that Aura Biosciences is being referred to more favorably in the media.
Aura Biosciences presently has a consensus price target of $23.00, suggesting a potential upside of 196.01%. Atara Biotherapeutics has a consensus price target of $17.75, suggesting a potential upside of 170.17%. Given Aura Biosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Aura Biosciences is more favorable than Atara Biotherapeutics.
Aura Biosciences has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -132.58%. Atara Biotherapeutics' return on equity of 0.00% beat Aura Biosciences' return on equity.
Atara Biotherapeutics received 413 more outperform votes than Aura Biosciences when rated by MarketBeat users. Likewise, 67.60% of users gave Atara Biotherapeutics an outperform vote while only 62.16% of users gave Aura Biosciences an outperform vote.
96.8% of Aura Biosciences shares are held by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are held by institutional investors. 5.4% of Aura Biosciences shares are held by company insiders. Comparatively, 3.7% of Atara Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Aura Biosciences has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500. Comparatively, Atara Biotherapeutics has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500.
Aura Biosciences has higher earnings, but lower revenue than Atara Biotherapeutics. Aura Biosciences is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Aura Biosciences beats Atara Biotherapeutics on 10 of the 17 factors compared between the two stocks.
Get Atara Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATRA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Atara Biotherapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ATRA) was last updated on 1/18/2025 by MarketBeat.com Staff
Free ATRA Stock Alerts